Sandoz Australia & New Zealand

Name

Sandoz Australia & New Zealand

Legal name

Sandoz Australia

Website

https://sandoz.com.au

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologics & Biosimilars Distributors (HLAIAJAH)

akta.pro secondary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

Keywords

• Generic pharmaceuticals
• Biosimilar medicines
• Ophthalmic biosimilars
• Pharmaceutical licensing
• Affordable medicines

Headquarters

HQ city

North Sydney

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Core offering

Sandoz Australia & New Zealand is a pharmaceutical company specializing in the development, commercialization, and distribution of generic and biosimilar medicines in the Australian and New Zealand markets. The company sells an aflibercept biosimilar for ophthalmic conditions (launched November 2025) and holds Australian commercial rights for a TPM®-enhanced CBD capsule for insomnia under license from Avecho Biotechnology.

Product overview

Sandoz Australia & New Zealand is a pharmaceutical company specializing in generic and biosimilar medicines. The company's product portfolio includes the aflibercept biosimilar (launched November 2025) and the TPM®-enhanced CBD capsule (under license from Avecho Biotechnology). Sandoz operates as part of the global Sandoz network, focusing on making medicines more accessible through generic and biosimilar alternatives.

Differentiator

Problem solved

Functional benefit

Products and services

• Aflibercept Biosimilar A biosimilar version of aflibercept used for treating eye conditions such as wet age-related macular degeneration. Launched by Sandoz in Australia following resolution of patent litigation with Regeneron and Bayer. Distributed to ophthalmologists and healthcare providers in Australia.
• TPM®-enhanced CBD Capsule A CBD (cannabidiol) capsule enhanced with Avecho's TPM® (Tocopherol Phosphate Mixture) technology for improved bioavailability, in development for insomnia treatment. Sandoz holds Australian commercial rights under a licensing agreement with Avecho Biotechnology Limited. Targeted at patients with insomnia in Australia.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Avecho Biotechnology LimitedcoreOEM/ Whitelabel/ Licensing PartnerSandoz holds Australian commercial rights for Avecho's TPM®-enhanced CBD capsule for insomnia, licensed under a deal structure including US$3 million upfront payment and potential milestones of up to US$16 million plus royalties. Avecho conducted Phase III clinical trials with positive interim analysis, with Data Monitoring Board recommending continuation to full enrollment of 519 participants. The partnership positions Sandoz for commercialization of this novel insomnia treatment in the Australian market.
• Avecho Biotechnology LimitedcoreOEM/ Whitelabel/ Licensing PartnerAvecho granted Sandoz exclusive Australian commercial rights for its world-first TPM®-enhanced CBD capsule. The Phase III insomnia trial demonstrated safety with no serious adverse events across 244 participants. Sandoz's licensing arrangement supports commercial positioning while Avecho pursues ongoing licensing discussions outside Australia.

Recent moves4 records

Expansion highlights4 records

Regional players

• Alphapharm (Viatris subsidiary): Alphapharm is a long-established Australia-focused generic manufacturer (now part of Viatris), competing with Sandoz in the Australian generics retail and pharmacy channel across chronic disease and primary care therapies.

Direct peers

• Samsung Bioepis: Samsung Bioepis is a global biosimilar specialist with biosimilars approved in Australia (e.g., Brenzys, Hadlima, Ontruzant), directly competing with Sandoz in the same biosimilar indications and tenders.
• Teva Pharmaceuticals Australia: Teva Australia is a major generics manufacturer offering broad off-patent pharmaceutical products, directly competing with Sandoz's generic portfolio across both pharmacy and hospital channels in Australia.
• Apotex Australia: Apotex is one of the largest Canadian-headquartered generic manufacturers with an established Australian affiliate, competing with Sandoz in the high-volume generic prescription market in Australia.
• Mylan (Viatris) Australia: Viatris (formerly Mylan) is a leading global generics and biosimilars company with a strong Australian presence, directly competing with Sandoz in generic and biosimilar markets across multiple therapeutic areas.
• Amgen Australia: Amgen Australia markets originator biologics and biosimilars (e.g., AMGEVITA, Kanjinti) competing directly with Sandoz in the Australian biosimilar space across immunology and ophthalmology indications.

Broad incumbents

• Pfizer Australia: Pfizer Australia operates one of the largest pharmaceutical portfolios in the country, including biosimilars acquired through Hospira, overlapping with Sandoz in both generic sterile injectables and biosimilar immunology assets.
• Novartis Australia: Novartis Australia is the originator of several biologics now facing biosimilar competition, and is the former parent of the global Sandoz business; it is the closest 'sister' organisation with overlapping commercial infrastructure and therapeutic-area expertise.
• Bayer Australia: Bayer Australia is the originator marketer of Eylea (aflibercept) and was the direct patent counterparty in the Sandoz Federal Court case; it represents both a competitor and the originator that Sandoz is challenging with its biosimilar.

Emerging players

• Celltrion Healthcare Australia: Celltrion Healthcare has launched multiple biosimilars (Remsima, Herzuma, Truxima) in Australia, making it a directly comparable biosimilar competitor in the same tender and hospital channels Sandoz targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/sandoz_global
• Facebookfacebook.com/sandozglobal
• LinkedInlinkedin.com/company/sandoz-aunz

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sandoz Australia & New Zealand